Tema腫瘤學主動型ETF CANC 深 滬
已收盤 07-02 16:00:00 美东时间
41.8283
+1.018
+2.50%
華盛通- 最 高41.99
- 今 開41.22
- 成交量 1.87万股
- 最 低 40.985
- 昨 收 40.81
- 總市值 2.02亿
- 52周最高 41.99
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 25.1004
- 委 比 0.00%
- 總股本 483.00万
- 歷史最高 41.99
- 量 比 0.16
- 振 幅 2.46%
- 歷史最低 20.0759
- 每 手 1
- 風險率 4.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Zydus Lifesciences Signs MoU With Apollo Hospitals
BRIEF-Zydus Lifesciences Signs MoU With Apollo Hospitals July 3 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS : ZYDUS LIFESCIENCES - ZYDUS SIGNS MOU WITH APOLLO HOSPITALS ZYDUS LIFESCIENCES - MOU TO EXPAND ACCESS TO SHIELD MULTI-CANCER DETECTION TEST Source text: ID:nnAZN4T5TTZ Further company covera
07-03 14:50
ANALYSIS-US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
ANALYSIS-US prices for new drugs fell in 2025 as fewer costly gene therapies were launched Median annual list price for drugs approved by FDA in 2025 was $216,000 The FDA approved 51 new drugs in 2025, including five cell and gene therapies More than 67% of 2025 approvals were small-molecule drugs,
06-25 18:00
BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer
BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer June 24 (Reuters) - Natera Inc NTRA.O : SIGNATERA™ RECEIVES REGULATORY APPROVAL IN JAPAN FOR COLORECTAL CANCER NATERA INC - NATERA EXPECTS TO COMMERCIALLY LAUNCH SIGNATERA FOR CRC IN JAPAN BY END OF 2026 Source t
06-24 15:01
UPDATE 3-GSK boosts lung cancer portfolio with $10.6 billion Nuvalent takeover
UPDATE 3-GSK boosts lung cancer portfolio with $10.6 billion Nuvalent takeover Deal values Nuvalent at $124 per share, a 40% premium to last close CEO Luke Miels says acquisition expands lung cancer treatments GSK expects deal to contribute to sales and operating profit from 2027 Adds details on dea
06-09 14:06
BRIEF-Tango Therapeutics Announces Combination Of Vopimetostat And Daraxonrasib Demonstrated 92% Objective Response Rate In Pancreatic Cancer
BRIEF-Tango Therapeutics Announces Combination Of Vopimetostat And Daraxonrasib Demonstrated 92% Objective Response Rate In Pancreatic Cancer June 8 (Reuters) - Tango Therapeutics Inc TNGX.O : TANGO THERAPEUTICS ANNOUNCES COMBINATION OF VOPIMETOSTAT AND DARAXONRASIB DEMONSTRATED 92% OBJECTIVE RESPON
06-08 19:01
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305
05-28 04:14
BRIEF-Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer
BRIEF-Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer May 14 (Reuters) - Silexion Therapeutics Corp SLXN.O : SILEXION THERAPEUTICS REPORTS POSITIVE PRELIMINARY IMMUNOTHERAPY FINDINGS FOR SIL204 IN KRAS-DRIVEN PANCREATIC CANCER Sou
05-14 21:30
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter finan...
05-13 17:16
BRIEF-Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
BRIEF-Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer May 5 (Reuters) - Sensei Biotherapeutics Inc SNSE.O : SENSEI BIOTHERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 TRIAL OF PIKTOR IN HR+/HER2- ADVANCED BREAST CANCER SENSEI BIOTHERAPEUTICS
05-05 19:52
BRIEF-Spirit Airlines Begins Orderly Wind-Down Of Operations
BRIEF-Spirit Airlines Begins Orderly Wind-Down Of Operations May 2 (Reuters) - Spirit Aviation Holdings Inc FLYYQ.PK : SPIRIT AIRLINES BEGINS ORDERLY WIND-DOWN OF OPERATIONS SPIRIT AIRLINES- ALL FLIGHTS HAVE BEEN CANCELLED SPIRIT AIRLINES- RECENT MATERIAL INCREASE IN OIL PRICES AND OTHER PRESSURES O
05-02 14:27
